COVID-19 VACCINE: PHASE 3 TRIALS HAVE STARTED SAYS US BIOTECH FIRM NOVAVAX

Highlights

• Gregory Glenn, Novavax’s president of research and development said that with a high level of SARS-CoV-2 transmission observed and expected to continue in the United Kingdom

• The US government had awarded $1.6 billion to Novavax to develop and fund the drug, which is administered by two intramuscular injections. 

• the company is optimistic that pivotal Phase 3 clinical tria....